Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathies

24 Nov 2023

Abstract excerpt

Overexpression of SNCA has been implicated in the pathogenesis of synucleinopathies, particularly Parkinson's disease (PD) and dementia with Lewy bodies (DLB). While PD and DLB share some clinical and pathological similarities, each disease presents distinct characteristics, including the primary affected brain region and neuronal type. We aimed to develop neuronal-type-specific SNCA -targeted epigenome therapies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Genetic Neurodegenerative Diseases
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38130373
DOI: 10.1016/j.omtn.2023.102084

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathiesPMID 38130373Read ↗

<i>SNCA</i> -targeted epigenome therapy for Parkinson’s disease alleviates pathological and behavioral perturbations in a mouse modelSemantic proximity Read ↗

CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson’s diseaseSemantic proximity Read ↗

Targeted attenuation of elevated histone marks at SNCA alleviates α‐synuclein in Parkinson's diseaseSemantic proximity Read ↗

Nuclease-dead S. <i>aureus</i> Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in patient-derived stem cell model of Parkinson’s diseaseSemantic proximity Read ↗

Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson’s diseaseSemantic proximity Read ↗

Neuronal titration of <i>Snca</i> via enhancer disruption mitigates disease onset in a Parkinson’s disease mouse modelSemantic proximity Read ↗

Global Effects of a PD Risk-SNP at the Alpha-Synuclein LocusSemantic proximity Read ↗

Finding the 'Guilty' Gene Variant of Sporadic Parkinson's Disease Via CRISPR/Cas9.Semantic proximity Read ↗

Advancements in CRISPR-Based Therapies for Genetic Modulation in Neurodegenerative Disorders.Semantic proximity Read ↗

Epigenetic regulation in Parkinson's disease.Semantic proximity Read ↗

CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease In Vivo.Semantic proximity Read ↗

Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated mutation of the SNCA geneSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.